Arkolith/Insider Trading/ALMR/Form 4

Naclerio Nicholas

DirectorAlamar Biosciences, Inc. (ALMR) · full profile →Form 4 · filed Apr 20, 2026
Net Buying
Open-Market Buys
$4.0M
Open-Market Sells
$0
Net Open-Market Flow
$4.0M
Transactions
13
8 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 20, 2026Conversion(C)4.6M——4.6M
Apr 20, 2026Conversion(C)922K——5.5M
Apr 20, 2026Other(J)5.5M——0
Apr 20, 2026Other(J)5.5M——5.5M
Apr 20, 2026Conversion(C)346K——5.9M
Apr 20, 2026Conversion(C)272K——272K
Apr 20, 2026Buy(P)235K$17.00$4.0M507K
Apr 20, 2026Grant(A)6K—$06K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 20, 2026Conversion(C)3.2M—$00
Apr 20, 2026Conversion(C)2.9M—$00
Apr 20, 2026Conversion(C)2.1M—$00
Apr 20, 2026Conversion(C)5.0M—$00
Apr 16, 2026Grant(A)26K—$026K

Transaction Codes

C
Conversion of a derivative
J
Other acquisition / disposition
P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001534166-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML